CD27/CD70与特发性肺纤维化

doi:10.16352/j.issn.1001-6325.2024.08.1170

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (8): 1170-1174.doi: 10.16352/j.issn.1001-6325.2024.08.1170

CD27/CD70与特发性肺纤维化

徐云聪, 郑金旭^*

江苏大学附属医院呼吸与危重症医学科,江苏镇江 212000

收稿日期:2024-03-11 修回日期:2024-05-29 出版日期:2024-08-05 发布日期:2024-07-24
通讯作者: ^*jxuzh135@163.com
基金资助:
镇江市重大(社会发展)项目(SH2018048);苏州市社会发展(民生医疗)项目(SYSD2020010):江苏大学医教协同创新基金(JDYY2023034)

CD27/CD70 and idiopathic pulmonary fibrosis

XU Yuncong, ZHENG Jinxu^*

Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang 212000, China

Received:2024-03-11 Revised:2024-05-29 Online:2024-08-05 Published:2024-07-24
Contact: ^*jxuzh135@163.com

摘要/Abstract

摘要： 特发性肺纤维化(IPF)是一种慢性间质性肺病,成纤维细胞、巨噬细胞和淋巴细胞在其中发挥重要作用。CD27/CD70轴通过分子通路与肺部免疫细胞的协同作用影响肺纤维化区域的免疫微环境,并在肺纤维化早期起到一定抑制作用,有望成为IPF免疫治疗的新靶点。

关键词: 特发性肺纤维化, CD27/CD70轴, PI3K/AKT通路

Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease marked by the significant involvement of fibroblasts, macrophages and lymphocytes. The CD27/CD70 axis is pivotal in shaping the immune microenvironment present in the fibrotic aeras of lungs. This mentioned interaction involves molecular pathways that work in tandem with lung immune cells, particularly exerting a suppressive influence in the early phases of pulmonary fibrosis. Consequently, the CD27/CD70 axis presents a promising new target for immunotherapy in IPF.

Key words: idiopathic pulmonary fibrosis, CD27/CD70 axis, PI3K/AKT pathway

中图分类号:

R563.9

徐云聪, 郑金旭. CD27/CD70与特发性肺纤维化[J]. 基础医学与临床, 2024, 44(8): 1170-1174.

XU Yuncong, ZHENG Jinxu. CD27/CD70 and idiopathic pulmonary fibrosis[J]. Basic & Clinical Medicine, 2024, 44(8): 1170-1174.

参考文献

[1] Cottin V, Martinez FJ, Jenkins RG, et al. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial[J]. Respir Res, 2022, 23: 85.doi:10.1186/s12931-022-01974-2.
[2] Moss BJ, Ryter SW, Rosas IO. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis[J]. Annu Rev Pathol, 2022, 17: 515-546.doi:10.1146/annurev-pathol-042320-030240.
[3] Yao C, Guan X, Carraro G, et al. Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2021, 203: 707-717.doi:10.1164/rccm.202004-1274OC.
[4] Löfdahl A, Nybom A, Wigén J, et al. Pulmonary 5-HT(2B) receptor expression in fibrotic interstitial lung diseases[J]. Acta Histochem, 2023, 125: 152024.doi:10.1016/j.acthis.2023.152024.
[5] Lebel M, Cliche DO, Charbonneau M, et al. Invadosome formation by lung fibroblasts in idiopathic pulmonary fibrosis[J]. Int J Mol Sci, 2022, 24.doi:10.3390/ijms24010499.
[6] Richter J, Oschlies I, Kock K, et al. CD27/CD70 pathway activation in primary cutaneous CD4⁺ small/medium T-cell lymphoproliferative disorder[J]. J Pathol, 2024, 262: 189-197.doi:10.1002/path.6222.
[7] Jaeger-Ruckstuhl CA, Lo Y, Fulton E, et al. Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks[J]. Immunity, 2024, 57: 287-302.doi:10.1016/j.immuni.2024.01.011.
[8] Cagnet L, Neyrinck-Leglantier D, Tamagne M, et al. CD27(+) microparticle interactions and immunoregulation of CD4(+) T lymphocytes[J]. Front Immunol, 2023, 14: 1043255.doi:10.3389/fimmu.2023.1043255.
[9] Bowakim-Anta N, Acolty V, Azouz A, et al. Chronic CD27-CD70 costimulation promotes type 1-specific polarization of effector Tregs[J]. Front Immunol, 2023, 14: 1023064.doi:10.3389/fimmu.2023.1023064.
[10] Serezani APM, Pascoalino BD, Bazzano JMR, et al. Multiplatform single-cell analysis identifies immune cell types enhanced in pulmonary fibrosis[J]. Am J Respir Cell Mol Biol, 2022, 67: 50-60.doi:10.1165/rcmb.2021-0418OC.
[11] Liu YZ, Saito S, Morris GF, et al. Proportions of resting memory T cells and monocytes in blood have prognostic significance in idiopathic pulmonary fibrosis[J]. Genomics, 2019, 111: 1343-1350.doi:10.1016/j.ygeno.2018.09.006.
[12] Inui N, Sakai S, Kitagawa M. Molecular pathogenesis of pulmonary fibrosis, with focus on pathways related to TGF-β and the ubiquitin-proteasome pathway[J]. Int J Mol Sci, 2021, 22.doi:10.3390/ijms22116107.
[13] Tran-Nguyen TK, Xue J, Feghali-Bostwick C, et al. CD70 activation decreases pulmonary fibroblast production of extracellular matrix proteins[J]. Am J Respir Cell Mol Biol, 2020, 63: 255-265.doi:10.1165/rcmb.2019-0450OC.
[14] Wasiuk A, Weidlick J, Sisson C, et al. Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice[J]. Cancer Immunol Immunother, 2022, 71: 97-109.doi:10.1007/s00262-021-02958-9.
[15] Allard-Chamard H, Kaneko N, Bertocchi A, et al. Extrafollicular IgD(-)CD27(-)CXCR5(-)CD11c(-) DN3 B cells infiltrate inflamed tissues in autoimmune fibrosis and in severe COVID-19[J]. Cell Rep, 2023, 42: 112630.doi:10.1016/j.celrep.2023.112630.
[16] van Gisbergen KP, van Olffen RW, van Beek J, et al. Protective CD8 T cell memory is impaired during chronic CD70-driven costimulation[J]. J Immunol, 2009, 182: 5352-5362.doi:10.4049/jimmunol.0802809.
[17] Janho Dit Hreich S, Juhel T, Leroy S, et al. Activation of the P2RX7/IL-18 pathway in immune cells attenuates lung fibrosis[J]. Elife, 2024, 12.doi:10.7554/eLife.88138.
[18] Hult EM, Gurczynski SJ, Moore BB. M2 macrophages have unique transcriptomes but conditioned media does not promote profibrotic responses in lung fibroblasts or alveolar epithelial cells in vitro[J]. Am J Physiol Lung Cell Mol Physiol, 2021, 321: l518-l532.doi:10.1152/ajplung.00107.2021.
[19] Yang P, Luo Q, Wang X, et al. Comprehensive analysis of fibroblast activation protein expression in interstitial lung diseases[J]. Am J Respir Crit Care Med, 2023, 207: 160-172.doi:10.1164/rccm.202110-2414OC.
[20] Nascimento Júnior JXD, Sola-Penna M, Zancan P. Clotrimazole reverses macrophage M2 polarization by disrupt-ing the PI3K/AKT/mTOR pathway[J]. Biochem Biophys Res Commun, 2023, 696: 149455.doi:10.1016/j.bbrc.2023.149455.
[21] Wu Y, Zhang J, Wang X, et al. Saikosaponin-d regulates angiogenesis in idiopathic pulmonary fibrosis through angiopoietin/Tie-2 pathway[J]. Acta Histochem, 2023, 125: 152100.doi:10.1016/j.acthis.2023.152100.
[22] Pandey AK, Waldeck-Weiermair M, Wells QS, et al. Expression of CD70 modulates nitric oxide and redox status in endothelial cells[J]. Arterioscler Thromb Vasc Biol, 2022, 42: 1169-1185.doi:10.1161/atvbaha.122.317866.
[23] Xu Z, Davies ER, Yao L, et al. LKB1 depletion-mediated epithelial-mesenchymal transition induces fibroblast activation in lung fibrosis[J]. Genes Dis, 2024, 11: 101065.doi:10.1016/j.gendis.2023.06.034.
[24] Ortiz-Cuaran S, Swalduz A, Foy JP, et al. Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer[J]. Eur J Cancer, 2022, 169: 106-122.doi:10.1016/j.ejca.2022.03.038.
[25] Thillai M, Oldham JM, Ruggiero A, et al. Deep learning-based segmentation of CT scans predicts disease progression and mortality in IPF[J]. Am J Respir Crit Care Med, 2024.doi:10.1164/rccm.202311-2185OC.

CD27/CD70与特发性肺纤维化

CD27/CD70 and idiopathic pulmonary fibrosis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	段然, 李青原, 冯同. 代谢重编程在特发性肺纤维化发病中的作用[J]. 基础医学与临床, 2024, 44(6): 882-886.
[2]	孙丹房立平耿彬刘新民唐朝枢. 特发性肺纤维化患者血硫化氢水平下降[J]. 基础医学与临床, 2010, 30(2): 122-124.